Sildenafil Citrate Orally Disintegrating Tablets (Drug Registration Certificate) - Sharpaisi

Shapsis Announcement: Recently, the company has received the "Drug Registration Certificate" for Sildenafil Citrate Orally Disintegrating Tablets issued by the National Medical Products Administration. The orally disintegrating tablets of Sildenafil Citrate approved this time are used for the treatment of erectile dysfunction. As of the disclosure date of this announcement, the company's cumulative research and development investment for this drug is approximately 9.915 million RMB.